Nitroprusside Pediatric Dose — Cardiovascular Infusions
Nitroprusside is a potent, rapidly acting vasodilator that reduces both preload and afterload through direct nitric oxide–mediated smooth muscle relaxation. It is used in the pediatric intensive care setting for hypertensive emergencies and acute heart failure requiring precise, titratable blood pressure control.
Pediatric Dosing
- Standard dose (children <40 kg): 0.5–5 mcg/kg/min by continuous IV infusion. Titrate in small increments based on hemodynamic response.
- Initial infusion in adults or patients ≥40 kg: 0.1 mcg/kg/min, titrated to effect.
Worked example: For a 20 kg child, the starting infusion range would be 20 × 0.5 mcg/kg/min = 10 mcg/min up to a maximum of 20 × 5 mcg/kg/min = 100 mcg/min. Consult institutional protocol for exact concentration, maximum duration, and upper dose limits.
Indications and Clinical Context
Nitroprusside is indicated for hypertensive emergencies requiring rapid, precise blood pressure reduction, and for afterload reduction in acute decompensated heart failure or low cardiac output states in the PICU. Its ultra-short duration of action (seconds to minutes) allows for minute-to-minute titration under continuous arterial pressure monitoring, making it valuable when other agents cannot achieve adequate control.
Due to its potency and potential for toxicity, nitroprusside is generally reserved for situations where the clinical benefit outweighs risk, and it is administered only in a closely monitored critical care environment consistent with institutional and evidence-based pediatric critical care guidelines.
Administration and Monitoring
Nitroprusside must be administered exclusively by continuous IV infusion via a dedicated central or peripheral line using a calibrated infusion pump. The solution is highly light-sensitive; protect the infusion bag and tubing from light throughout administration. Continuous intra-arterial blood pressure monitoring is strongly recommended given the rapid onset and offset of effect.
- Route: IV infusion only — no bolus administration.
- Light protection: Wrap infusion bag in opaque material; replace tubing per institutional policy.
- Cyanide/thiocyanate toxicity: Risk increases with high doses, prolonged infusion (>24–48 hours), or renal/hepatic impairment. Monitor for metabolic acidosis, tachyphylaxis, or neurological changes.
- Hypotension: The primary adverse effect; titrate slowly and monitor continuously.
- Consult institutional protocol for maximum cumulative dose, infusion duration limits, and thiocyanate monitoring intervals.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.